This inventor holds 1 USPTO granted patent. Top assignees: Oregon Health & Science University, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2019.
Company Filing History:
1 out of 524 
1 out of 3,688 
Years Active: 2019
Title: Melvin Doster: Innovator in HIV Research
Introduction
Melvin Doster is a notable inventor based in Beltsville, MD (US). He has made significant contributions to the field of HIV research, particularly in developing methods to improve vaccine efficacy. His innovative work has the potential to impact the way HIV infections are treated and prevented.
Latest Patents
Doster holds a patent titled "Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy." This patent discloses compositions that include a therapeutically effective amount of an HIV immunogen combined with an agent that stimulates the Ras pathway, excluding aluminum salts. The methods outlined in the patent aim to induce an immune response to HIV and inhibit or treat HIV infection in subjects. Additionally, the patent describes methods for determining the effectiveness of immunogenic compositions in inducing protective responses against HIV.
Career Highlights
Throughout his career, Melvin Doster has worked with reputable organizations, including Oregon Health & Science University and the United States Department of Health and Human Services. His work in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Doster has collaborated with notable colleagues such as Shari Gordon and Mark Cameron. These partnerships have furthered his research efforts and enhanced the impact of his work in HIV immunology.
Conclusion
Melvin Doster's innovative contributions to HIV research and vaccine development highlight his role as a significant inventor in the field. His patent and collaborations reflect a commitment to advancing medical science and improving health outcomes for individuals affected by HIV.